Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
African Americans with interstitial lung disease (ILD) caused by scleroderma (SSc-ILD) had largely similar outcomes compared to non‐African Americans in two clinical trials testing immunosuppressive therapies, according to an analysis. ... Read more
Brain cancer associated with a viral infection was found in two people with scleroderma after doses of their immunosuppressive therapies were reduced, a case series reports. The findings suggest ... Read more
Treatment with abatacept led to a reduction in skin stiffening and disability, as well as better overall health, in people with early diffuse cutaneous scleroderma (dcSSc) who participated in ... Read more
Rituximab, in combination with CellCept (mycophenolate mofetil), reverses the decline in lung function in people with interstitial lung disease (ILD) associated with scleroderma (SSc) who did not respond to ... Read more
A triple combination of prednisolone, cyclophosphamide and plasma exchange (plasmapheresis) was effective against skin thickening in seven of eight people with diffuse cutaneous systemic sclerosis (dcSSc), a case series study reports. ... Read more
EHP-101, an oral therapy based on cannabidiol (CBD), has been placed on fast track development by the U.S. Food and Drug Administration (FDA) as a potential treatment of systemic scleroderma. ... Read more
A statistical model applied to a widely used measure of skin thickening in people newly diagnosed with systemic sclerosis (SSc) identified five classes that may predict organ involvement and survival ... Read more